P.3.e.003 The cost and effects of atypical antipsychotic agents in patients with schizophrenia in Slovenia: a cost effectiveness study

2013 ◽  
Vol 23 ◽  
pp. S491-S492
Author(s):  
M. Stuhec ◽  
D. Petrica ◽  
J. Toni
Keyword(s):  
Cost Effectiveness ◽  
Atypical Antipsychotic ◽  
Antipsychotic Agents ◽  
Effectiveness Study ◽  
Atypical Antipsychotic Agents ◽  
The Cost ◽  
Cost Effectiveness Study

scholarly journals Strošek In Učinkovitost Zdravljenja Shizofrenije Z Atipičnimi Antipsihotiki V Sloveniji: Raziskava Stroškovne Učinkovitosti / The Cost And Effects Of Atypical Antipsychotic Agents In Patients With Schizophrenia In Slovenia: A Cost Effectiveness Study

2013 ◽  
Vol 52 (1) ◽  
pp. 27-38 ◽  
Author(s):  
Matej Štuhec ◽  
Demetrij Petrica ◽  
Janez Toni
Keyword(s):  
Cost Effectiveness ◽  
Atypical Antipsychotic ◽  
Antipsychotic Agents ◽  
Effectiveness Study ◽  
Atypical Antipsychotic Agents ◽  
The Cost ◽  
Cost Effectiveness Study

Izvleček Uvod: Zdravljenje z atipičnimi antipsihotiki predstavlja najpomembnejši način zdravljenja bolnikov z akutno shizofrenijo in predstavlja veliki strošek. V Sloveniji nam primanjkuje raziskav stroškovne učinkovitosti atipičnih antipsihotikov, ki jih lahko uporabimo v klinični praksi. Namen: Osnovni namen raziskave je bil primerjava stroškov in učinkovitosti petih atipičnih antipsihotikov z največjim tržnim deležem v letu 2011 v Sloveniji. V raziskavo smo vključili aripiprazol, kvetiapin, paliperidon, risperidon in olanzapin. Metode: Ciljna populacija v raziskavi so bili slovenski bolniki z akutno shizofrenijo. Vsak izmed petih antipsihotikov predstavlja glavno vejo odločitvenega drevesa. Terapevtska učinkovitost je bila določena kot verjetnost letne remisije. Ceno dnevnega zdravljenja s posameznim zdravilom smo pridobili iz podatkov tržnega deleža in prometa v letu 2011, stroške mentalnega zdravstvenega varstva v Sloveniji pa smo pridobili iz podatkov Zavoda za zdravstveno zavarovanje Republike Slovenije. Raziskava je bila zasnovana z vidika plačnika, tj. Zavoda za zdravstveno zavarovanje Republike Slovenije. Rezultati: Zdravljenje z risperidonom je najcenejše, najučinkovitejše pa z olanzapinom. Strategija zdravljenja z risperidonom ima najmanjši kvocient med stroški in učinkovitostjo. Strategije zdravljenja z aripiprazolom, s kvetiapinom in paliperidonom so prevladujoče. Cene letnega zdravljenja so: 6.812 EUR za risperidon, 7.509 EUR za kvetiapin, 7.295 EUR za olanzapin, 8.229 EUR za aripiprazol in 8.044 EUR za paliperidon. Učinkovitosti, podane v deležu letne remisije, so: 0,605 - kvetiapin, 0,603 - aripiprazol, 0,671 - risperidon, 0,723 - olanzapin in 0,712 - paliperidon. Sklep: Rezultati študije kažejo, da je najbolj stroškovno učinkovito zdravljenje akutne shizofrenije z risperidonom in olanzapinom

scholarly journals Is your syringe services program cost-saving to society? A methodological case study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Don C. Des Jarlais ◽  
Jonathan Feelemyer ◽  
Courtney McKnight ◽  
Kelly Knudtson ◽  
Sara N. Glick
Keyword(s):  
Cost Effectiveness ◽  
Cost Saving ◽  
Hiv Infection ◽  
Hiv Transmission ◽  
Hiv Infections ◽  
Effectiveness Study ◽  
Persons Who Inject Drugs ◽  
Annual Budget ◽  
The Cost ◽  
Cost Effectiveness Study

Abstract Background While there is a general acceptance among public health officials and policy-makers that syringe services programs can be effective in reducing HIV transmission among persons who inject drugs, local syringe services programs are often asked to provide economic justifications for their activities. A cost-effectiveness study, estimating the cost of preventing one HIV infection, would be the preferred methods for addressing this economic question, but few local syringe services programs have the needed data, staff and epidemiologic modeling resources needed for a cost–effectiveness study. We present a method for estimating a threshold value for the number of HIV infections prevented above which the program will be cost-saving to society. An intervention is considered “cost-saving” when it leads to a desirable health outcome a lower cost than the alternative. Methods The research literature on the effectiveness of syringe services programs in controlling HIV transmission among persons who inject drugs and guidelines for syringe services program that are “functioning very well” were used to estimate the cost-saving threshold at which a syringe services program becomes cost-saving through preventing HIV infections versus lifetime treatment of HIV. Three steps are involved: (1) determining if HIV transmission in the local persons who inject drugs (PWID) population is being controlled, (2) determining if the local syringe services program is functioning very well, and then (3) dividing the annual budget of the syringe services program by the lifetime cost of treating a single HIV infection. Results A syringe services program in an area with controlled HIV transmission (with HIV incidence of 1/100 person-years or less), functioning very well (with high syringe coverage, linkages to other services, and monitoring the local drug use situation), and an annual budget of $500,000 would need to prevent only 3 new HIV infections per year to be cost-saving. Conclusions Given the high costs of treating HIV infections, syringe services programs that are operating according to very good practices (“functioning very well”) and in communities in which HIV transmission is being controlled among persons who inject drugs, will almost certainly be cost-saving to society.

A Comparative Cost-Effectiveness Study of Two Treatment Modalities for Ragweed Hay Fever

1989 ◽  
Vol 3 (2) ◽  
pp. 99-104 ◽  
Author(s):  
Frederick E. Leickly ◽  
Dolores Sears-Ewald ◽  
Dennis R. Ownby
Keyword(s):  
Allergic Rhinitis ◽  
Cost Effectiveness ◽  
Low Dose ◽  
Hay Fever ◽  
Treatment Modalities ◽  
Effectiveness Study ◽  
Cost Of Treatment ◽  
Comparative Cost ◽  
The Cost ◽  
Cost Effectiveness Study

The cost of treatment for ragweed hay fever can vary considerably. The newer classes of antihistamines are purported to be effective and without major side effects, but they are costly. This study compared the cost-effectiveness of terfenadine and chlorpheniramine/pseudoephedrine. We found that the maximum use of a low dose of chlorpheniramine/pseudoephedrine was effective and without major daytime sedation and should be considered when treatment for ragweed-induced allergic rhinitis is begun.

Sign in / Sign up

Export Citation Format

Share Document